MedTrace Logo

A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

NCT02902809 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-09-06

Study results available
· View outcomes & findings →

Summary

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid plus Long-Acting β2-Agonist

Conditions

  • Inadequately Controlled Asthma

Interventions

BIOLOGICAL

Tralokinumab open-label

Subcutaneous injection; fixed dose; 300 mg

Sponsors & Collaborators

Principal Investigators

  • Takeshi Kaneko, MD, PhD · Yokohama City University Graduate School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-11
Primary Completion
2018-01-19
Completion
2018-01-19

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02902809 on ClinicalTrials.gov